Business Wire

INCUBETA

13.1.2021 13:14:36 CET | Business Wire | Press release

Share
Lars Lehne Appointed as Group CEO of Incubeta

Lars Lehne has been appointed Group CEO of Incubeta , the independent digital marketing services group. The former SYZYGY AG CEO will be taking over from the founder Alan Lipschitz, whose company Interface made the reverse acquisition of IncuBeta Holdings in 2011. Alan will be moving into the role of Chairperson of the Board of Directors of Incubeta.

Lars brings with him more than 30 years of industry experience. Prior to Incubeta Lars spent four years as Global CEO at SYZYGY, a publicly listed WPP company. Before that, he spent seven years at Google as Country Director Agency DACH, paving the way for the tech giant quadrupling revenues in Germany. He has also held various senior management positions in agencies including Maxus, GroupM, Carat and MEC.

In addition to his current role as new Group CEO of Incubeta, Lars is a member of the advisory board of Yext, and betterplace.org, a Berlin based NGO. He’s also an Angel Investor in CLAIMINI GmbH. As Group CEO, Lars will be leading company positioning and growth, including its operations in North America, driving the business strategy and further uniting the group across the globe.

Incubeta operates across 14 countries with offices in cities including London, New York, Los Angeles, Madrid, Sydney and Cape Town. In 2013 the highly successful Net Media Planet (NMPi) was acquired, which established significant growth for Incubeta as it boosted its advertising offerings. The subsequent acquisition in 2016 of forward-thinking marketing technology specialist DQ&A, extended the company’s geographical and product growth. This was followed by the acquisition of market leading creative specialist, Joystick, in 2018. Through these acquisitions, Incubeta offers clients a full suite of unrivalled services connecting Media, Technology and Creative.

In the last twelve months, Incubeta has launched several new innovative platforms. This has included the award-winning proprietary Seamless technology, including Seamless Search – which measures the incrementality of paid and organic SEO keywords – and Seamless Creative – which unifies media activity and creative assembly at scale. The company has also made a series of new appointments including senior hire John Cawdery as US CEO.

Alan Lipschitz, Founder and Chairperson of the Board, comments: “Having started a small South African business many years ago, I am so very proud of how far the company has come. By building a fantastic team around me and adding inspirational businesses from around the world, Incubeta has grown into a leading player in digital marketing services. The company is in a great place, yet I believe in order to accelerate pace and to meet the challenges of the future we need a different type of leader.

“I have the utmost faith Lars is the leader the company needs to take Incubeta forward. He has the expertise to bring the team further together, drive clear strategy, and build on the fantastic foundation I have been able to create with my wonderful team. So it is with great pride and pleasure that I hand the mantle of Chief Executive Officer of the Incubeta Group to Lars Lehne.”

Lars Lehne, Group CEO of Incubeta, comments: “I’m thrilled and honoured to be joining such a forward-thinking and innovative company. Incubeta has continued to grow during one of the most challenging years for the industry which is a testament to the quality and hard work of every team member across the globe. The company has flourished under Alan’s leadership and it's a great privilege that he’s trusting me to take his dream forward.

“As marketing continues to evolve at a rapid pace, it’s harder now than ever before for brands to connect with their customers. By integrating Media, Technology, and Creative in a seamless way Incubeta has developed the right services and products to help clients grow in a digital world. Incubeta puts the ownership of the customer experience back into the hands of its clients. I can’t wait to see what the next chapter for Incubeta looks like.”

-ENDS-

About Incubeta:

Incubeta is the union of three market leading specialists in Technology, Media, and Creative – DQ&A, NMPi, and Joystick respectively. By seamlessly integrating these three specialisms and rethinking the rules of marketing, Incubeta puts the ownership and control of the customer experience back in the hands of the advertiser, both brands and agencies.

As the largest and longest established GMP sales partner in EMEA and APAC, Incubeta has proven through working with top-tier brands that they are leading specialists in helping advertisers tackle complex projects such as in-housing, dynamic creative, data integration, real 1:1 marketing, and industry-specific segmentation modeling. Incubeta is primed to help advertisers deliver complex use cases across Google's Maturity Framework and Menu of Services.

Find out more at: incubeta.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye